Wellington Management Group LLP Acquires 520,898 Shares of Janux Therapeutics, Inc. (NASDAQ:JANX)

Wellington Management Group LLP boosted its stake in Janux Therapeutics, Inc. (NASDAQ:JANX - Free Report) by 3,592.9% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 535,396 shares of the company's stock after purchasing an additional 520,898 shares during the period. Wellington Management Group LLP owned about 1.02% of Janux Therapeutics worth $28,665,000 at the end of the most recent quarter.

Several other hedge funds also recently modified their holdings of the company. Avanza Fonder AB acquired a new stake in Janux Therapeutics during the fourth quarter worth approximately $139,000. Chicago Capital LLC acquired a new position in Janux Therapeutics during the 4th quarter worth approximately $230,000. Legato Capital Management LLC bought a new position in Janux Therapeutics in the fourth quarter worth approximately $347,000. Y Intercept Hong Kong Ltd acquired a new stake in Janux Therapeutics in the third quarter valued at approximately $317,000. Finally, Virtu Financial LLC lifted its holdings in shares of Janux Therapeutics by 48.0% in the 3rd quarter. Virtu Financial LLC now owns 7,463 shares of the company's stock worth $339,000 after purchasing an additional 2,419 shares in the last quarter. Institutional investors and hedge funds own 75.39% of the company's stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently weighed in on JANX shares. Scotiabank lowered their target price on shares of Janux Therapeutics from $62.00 to $41.00 and set a "sector perform" rating on the stock in a report on Friday, February 28th. HC Wainwright restated a "buy" rating and set a $70.00 price objective on shares of Janux Therapeutics in a research note on Monday, March 3rd. William Blair reiterated an "outperform" rating on shares of Janux Therapeutics in a research note on Friday, January 10th. Lifesci Capital raised shares of Janux Therapeutics to a "strong-buy" rating in a research report on Friday, December 27th. Finally, Wedbush restated an "outperform" rating and issued a $76.00 target price (up previously from $75.00) on shares of Janux Therapeutics in a research note on Friday, February 28th. One research analyst has rated the stock with a hold rating, nine have assigned a buy rating and two have given a strong buy rating to the company's stock. According to data from MarketBeat.com, the company presently has an average rating of "Buy" and an average target price of $92.44.

Remove Ads

Janux Therapeutics Stock Performance

JANX stock traded up $1.93 on Friday, reaching $28.80. The company's stock had a trading volume of 2,018,926 shares, compared to its average volume of 858,288. The firm has a market cap of $1.70 billion, a PE ratio of -24.62 and a beta of 3.27. Janux Therapeutics, Inc. has a 12-month low of $22.52 and a 12-month high of $71.71. The business has a fifty day simple moving average of $31.72 and a two-hundred day simple moving average of $44.16.

Janux Therapeutics (NASDAQ:JANX - Get Free Report) last posted its earnings results on Thursday, February 27th. The company reported ($0.36) earnings per share for the quarter, beating analysts' consensus estimates of ($0.49) by $0.13. Janux Therapeutics had a negative return on equity of 10.47% and a negative net margin of 463.91%. As a group, research analysts anticipate that Janux Therapeutics, Inc. will post -1.38 earnings per share for the current fiscal year.

Insider Activity at Janux Therapeutics

In other news, insider Andrew Hollman Meyer sold 3,334 shares of the business's stock in a transaction on Monday, February 3rd. The shares were sold at an average price of $42.29, for a total value of $140,994.86. Following the transaction, the insider now owns 82,139 shares of the company's stock, valued at approximately $3,473,658.31. The trade was a 3.90 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Ra Capital Management, L.P. purchased 110,206 shares of Janux Therapeutics stock in a transaction on Friday, March 7th. The stock was bought at an average price of $31.02 per share, for a total transaction of $3,418,590.12. Following the completion of the acquisition, the director now owns 10,141,287 shares in the company, valued at $314,582,722.74. The trade was a 1.10 % increase in their position. The disclosure for this purchase can be found here. 29.40% of the stock is owned by company insiders.

Janux Therapeutics Company Profile

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.